KR20230067647A - 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법 - Google Patents

리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법 Download PDF

Info

Publication number
KR20230067647A
KR20230067647A KR1020237012413A KR20237012413A KR20230067647A KR 20230067647 A KR20230067647 A KR 20230067647A KR 1020237012413 A KR1020237012413 A KR 1020237012413A KR 20237012413 A KR20237012413 A KR 20237012413A KR 20230067647 A KR20230067647 A KR 20230067647A
Authority
KR
South Korea
Prior art keywords
dosing
day
days
group
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237012413A
Other languages
English (en)
Korean (ko)
Inventor
히로유키 우에노
다쿠야 호시노
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20230067647A publication Critical patent/KR20230067647A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237012413A 2020-09-15 2021-09-15 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법 Withdrawn KR20230067647A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078844P 2020-09-15 2020-09-15
US63/078,844 2020-09-15
PCT/JP2021/033855 WO2022059692A1 (en) 2020-09-15 2021-09-15 Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor

Publications (1)

Publication Number Publication Date
KR20230067647A true KR20230067647A (ko) 2023-05-16

Family

ID=80776678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012413A Withdrawn KR20230067647A (ko) 2020-09-15 2021-09-15 리보뉴클레오티드 리덕타제 억제제를 사용한 리보뉴클레오티드 리덕타제-관련 질환의 치료 방법

Country Status (8)

Country Link
US (1) US20230390251A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213842B1 (cg-RX-API-DMAC7.html)
JP (1) JP7828333B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230067647A (cg-RX-API-DMAC7.html)
AU (1) AU2021345171A1 (cg-RX-API-DMAC7.html)
ES (1) ES3070493T3 (cg-RX-API-DMAC7.html)
TW (1) TW202227060A (cg-RX-API-DMAC7.html)
WO (1) WO2022059692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121453A2 (en) * 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
US10889555B2 (en) * 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
TWI748142B (zh) * 2017-11-29 2021-12-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑

Also Published As

Publication number Publication date
JP7828333B2 (ja) 2026-03-11
JP2023541432A (ja) 2023-10-02
AU2021345171A1 (en) 2023-05-25
US20230390251A1 (en) 2023-12-07
AU2021345171A9 (en) 2024-02-08
EP4213842B1 (en) 2026-04-15
TW202227060A (zh) 2022-07-16
WO2022059692A1 (en) 2022-03-24
EP4213842A1 (en) 2023-07-26
ES3070493T3 (en) 2026-06-16
EP4213842A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
JP7828333B2 (ja) リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法
TWI914404B (zh) 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法
CN113038953B (zh) 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法
US20240238300A1 (en) Treatment methods for subjects with cancer having an aberration in egfr and/or her2
WO2025006697A1 (en) Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr
AU2022355189B2 (en) Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
RU2848459C1 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
RU2859365C2 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
US20240408100A1 (en) Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway
WO2026015825A1 (en) Use of ras inhibitor for treating pancreatic cancer
WO2026072904A2 (en) Compositions and methods for treating lung cancer
HK40055650A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202